NEWS RELEASE

FIRST Live Implants of BioMatrix

Mark Approval® Drug-Eluting Stent in Europe Following CE

Leading cardiologists implanted six next-generation drug eluting stents in three patients

with complex heart diseases

Rome, 18 February 2008 ?

?Company?, Bloomberg: BIG SP) announced today that its BioMatrix

system was successfully implanted into the first European patients following its Conformité

Européenne (?CE?) Mark approval last month. Two leading cardiologists implanted a total of

six BioMatrix drug-eluting stents in three complex cases that were broadcast live during the

Joint Interventional Meeting 2008 (?JIM?). JIM is a leading meeting of interventional

cardiologists held annually and attended by cardiologists and physicians from around the

world. This scientific meeting, held in Rome, Italy, from 13 ? 15 February, focuses on live

demonstration of interventional procedures.

Professor Eberhard Grube, Chief of Cardiology at the Helios Heart Center in Siegburg,

Germany, and Dr. Gregg W. Stone, Director of Cardiovascular Research and Education at the

New York Presbyterian Hospital-Columbia Medical Center, performed the three procedures

at the Helios Heart Center in Siegburg. The first patient to receive BioMatrix was a 71-yearold

male who is suffering from diabetes and hypertension. He received two BioMatrix drugeluting

stents in a procedure performed by Prof Grube that was broadcast live to the more

than 1,500 attendees on the opening day of JIM.

?The three-year follow-up data released at the Transcatheter Coronary Therapeutics 2007

(?TCT 2007?) demonstrated BioMatrix?s consistent results in terms of safety and clinical

efficacy. This drug-eluting stent has shown excellent procedural performance and outcome

characteristics,? commented Professor Grube.

Prof. Grube also implanted a BioMatrix in a 56-year-old male patient to treat an artery that

became blocked due to restenosis, or re-narrowing, after being previously implanted with a

first-generation drug-eluting stent that utilizes durable polymer as a drug delivery

mechanism. Dr Stone implanted three BioMatrix stents in a third patient, a 57-year-old

male suffering from a totally blocked left anterior descending artery (LAD) and a partially

blocked right coronary artery (RCA). Despite the complicated patient conditions, the two

cardiologists implanted all six BioMatrix drug-eluting stents with 100% procedural success.

?The initial results from these implants are encouraging, and I am very optimistic about the

outcome for these patients, based on the consistently positive clinical trial results achieved

for BioMatrix. This drug-eluting stent system has an excellent deliverability and is especially

useful in treating patients with challenging medical conditions such as the three cases

presented at JIM. I am confident that BioMatrix can become a drug-eluting stent of choice

among cardiologists after it is fully commercialized,? added Professor Grube, who was

responsible for all three live transmissions from Siegburg.

BioMatrix, which received European regulatory approval in January 2008, is a unique drugeluting

stent system that combines a biodegradable polymer and the company?s proprietary

anti-restenotic drug, Biolimus A9

from April 2008.

?These first live implants since BioMatrix received the European regulatory approval are a

very significant milestone for Biosensors,? said Jeffrey B. Jump, Managing Director of

Biosensors Europe SA. ?We are confident that these will be the first of many thousands, as

physicians recognize the long-term benefits of our biodegradable drug delivery system over

earlier generations of drug-eluting stents.?Biosensors International Group Ltd. (?Biosensors? or the® drug-eluting stent®. The company plans a full European and Asian launch

### END OF RELEASE ###

Media Relations & Investor Relations

Biosensors International Group

Mr. Loh Chee Mun

Senior Vice President

Tel: (65) 6213 5708

Email: cm.loh@biosensors.com

Media Relations / Investor Relations Firm

United States

Allen & Caron Inc.

Mr. Matt Clawson

Executive Vice President, Investor Relations

Tel: (1) 949 474 4300

Email: matt@allencaron.com

About Biosensors International Group, Ltd

Biosensors develops, manufactures and markets innovative medical devices used in

interventional cardiology and critical care procedures. Biosensors is well-positioned to

emerge as a leader in drug-eluting stents and has developed a pipeline of next-generation

products that are set to gain market share from traditional therapies such as conventional

drug-eluting stents, bare-metal stenting and open-heart surgery. It has three separate drugeluting

stent programs,

drug-eluting stent.

For more information, please visit BioMatrix®, Axxion?, and BioFreedom?, a completely polymer-freewww.biosensors.com.

About BioMatrix®

BioMatrix

A9

designed for enhanced deliverability.

Biolimus A9 was designed specifically for use in drug-eluting stent systems. In addition to

effective immunosuppressive and anti-inflammatory properties, the drug has a higher

lipophilic and hydrophobic profile than other limus analogs, enabling rapid absorption of the

drug into the targeted tissue and reduced systemic exposure. Precision automated coating

ensures the PLA and drug combination is applied only to the abluminal (outer) surface of the

stent. The PLA fully degrades into water and carbon dioxide as the drug elutes, ultimately

leaving in place a biocompatible stent surface.

Biosensors will initiate several post marketing surveillance registries on the BioMatrix stent

in April collecting data on over 5000 patients with five year follow-up.

For more information, please visit ® offers the unique combination of an innovative anti-restenotic drug, Biolimus®, a biodegradable poly-lactic acid polymer (PLA), and an advanced, highly flexible stentwww.biomatrix.com

Forward-Looking Statements

Certain statements herein include forward-looking statements within the meaning of the

U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally

can be identified by the use of forward-looking terminology, such as ?may,? ?will,? ?expect,?

?intend,? ?estimate,? ?anticipate,? ?believe,? ?project? or ?continue? or the negative thereof

or other similar words. All forward looking statements involve risks and uncertainties,

including, but not limited to, customer acceptance and market share gains, competition from

companies that have greater financial resources; introduction of new products into the

marketplace by competitors; successful product development; dependence on significant

customers; the ability to recruit and retain quality employees as Biosensors grows; and

economic and political conditions globally. Actual results may differ materially from those

discussed in, or implied by, the forward-looking statements. The forward-looking statements

speak only as of the date of this release and Biosensors assumes no duty to update them to